Hi [[ session.user.profile.firstName ]]

Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic

Dr. Sonja Klebe of SA Pathology and Flinders University, Australia, will share data from two recently published studies investigating immunohistochemistry using various TTF-1 clones for diagnosis of lung cancer and metastases of other origins. She will discuss the sensitivity and specificity of the different TTF-1 clones and the resulting implications in identifying lung, prostate, and colorectal adenocarcinomas.
Recorded Dec 18 2019 36 mins
Your place is confirmed,
we'll send you email reminders
Presented by
A/Prof. Dr. Sonja Klebe, MD, PhD, FRCPA
Presentation preview: Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
CDx Insights
CDx Insights is a series brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Different TTF-1 clones for the diagnosis of lung tumors: primary vs. metastatic
  • Live at: Dec 18 2019 9:30 pm
  • Presented by: A/Prof. Dr. Sonja Klebe, MD, PhD, FRCPA
  • From:
Your email has been sent.
or close